The HST process is a method for evaluating medicines and treatments specifically indicated for ultra-orphan diseases that are unlikely to meet the typical HTA criteria.
Since it’s inception in 2015 only 14 guidance have been published. Our poster, originally prepared for the HTAi conference, explores whether the process has provided faster market access as it has intended, and how this has impacted patients.
We can help you navigate market access.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.